Actualités Merck & Co Inc - 0QAH | Actions London Stock Exchange

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Merck pembrolizumab combination therapy promising against lung cancer

Merck & Co Inc on Thursday released positive data on its combination therapy of pembrolizumab plus berahyaluronidase ...

IN BRIEF: Merck and Jiangsu Hengrui sign exclusive license agreement

Rahway, New Jersey-based pharmaceutical company - Enters into an exclusive license agreement with Jiangsu Hengrui Phar ...

Merck hits 2025 sales guidance; pauses Gardasil China shipments

Merck & Co Inc on Tuesday reported full-year sales in line with its guidance as management said it was "more confiden ...

IN BRIEF: Merck announces USD10 billion share buyback authorisation

New Jersey-based pharmaceutical company - Declares a quarterly dividend of USD0.81 per share for the second quarter of ...

IN BRIEF: Merck says HPV vaccines allegations "have no merit"

New Jersey-based pharmaceutical company - Issues statement defending the safety and efficacy of its HPV vaccines in li ...

Merck agrees USD1.9 billion deal with Hansoh to develop obesity drug

Merck & Co Inc on Wednesday struck a licensing deal with Hansoh Pharma to develop the Chinese biotech's oral obesity ...

IN BRIEF: Merck and AstraZeneca unveil long-term Lynparza results

d AstraZeneca PLC - Rahway, New Jersey and Cambridge, England-based pharmaceutical firms - Report positive long-term r ...

*Astrazencea and Merck & Co to continue trialling lynparza across multiple cancer types

...

*Merck & Co says lynparza linked to "clinically meaningful prolonged survival" of patients

...

*Astrazeneca partnered with Merck & Co on lynparza cancer treatment trial

...

*Merck & Co notes positive results in phase-3 trial of Lynparza breast cancer treatment

...

IN BRIEF: Merck trial shows Koselugo effective in treating adults

d AstraZeneca PLC - Pharmaceutical companies based in Rahway, New Jersey and Cambridge, England, respectively - Phase ...

Merck cuts earnings guidance as acquisitions weigh on bottom line

Merck & Co Inc on Thursday reported steady top-line growth, though profit took a hit due to the cost of recent acquis ...

IN BRIEF: Merck and Daiichi Sankyo's patritumab effective in phase 3

d Daiichi Sankyo Co Ltd - Rahway, New Jersey-based and Tokyo-based pharmaceutical companies - Joint-developed monoclon ...

TOP NEWS: Merck swings to second-quarter profit; trims profit guidance

Merck & Co Inc on Tuesday reported a swing to profit in the second quarter, but lowered its guidance for annual earni ...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Merck & Co Inc (0QAH)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

0QAH Actualités

Merck pembrolizumab combination therapy promising against lung cancer

IN BRIEF: Merck and Jiangsu Hengrui sign exclusive license agreement

Merck hits 2025 sales guidance; pauses Gardasil China shipments

IN BRIEF: Merck announces USD10 billion share buyback authorisation

IN BRIEF: Merck says HPV vaccines allegations "have no merit"

Merck agrees USD1.9 billion deal with Hansoh to develop obesity drug

IN BRIEF: Merck and AstraZeneca unveil long-term Lynparza results

*Astrazencea and Merck & Co to continue trialling lynparza across multiple cancer types

*Merck & Co says lynparza linked to "clinically meaningful prolonged survival" of patients

*Astrazeneca partnered with Merck & Co on lynparza cancer treatment trial

*Merck & Co notes positive results in phase-3 trial of Lynparza breast cancer treatment

IN BRIEF: Merck trial shows Koselugo effective in treating adults

Merck cuts earnings guidance as acquisitions weigh on bottom line

IN BRIEF: Merck and Daiichi Sankyo's patritumab effective in phase 3

TOP NEWS: Merck swings to second-quarter profit; trims profit guidance

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Merck & Co Inc (0QAH) Actualités

Merck & Co Inc (0QAH)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

0QAH Actualités

Merck pembrolizumab combination therapy promising against lung cancer

IN BRIEF: Merck and Jiangsu Hengrui sign exclusive license agreement

Merck hits 2025 sales guidance; pauses Gardasil China shipments

IN BRIEF: Merck announces USD10 billion share buyback authorisation

IN BRIEF: Merck says HPV vaccines allegations "have no merit"

Merck agrees USD1.9 billion deal with Hansoh to develop obesity drug

IN BRIEF: Merck and AstraZeneca unveil long-term Lynparza results

*Astrazencea and Merck & Co to continue trialling lynparza across multiple cancer types

*Merck & Co says lynparza linked to "clinically meaningful prolonged survival" of patients

*Astrazeneca partnered with Merck & Co on lynparza cancer treatment trial

*Merck & Co notes positive results in phase-3 trial of Lynparza breast cancer treatment

IN BRIEF: Merck trial shows Koselugo effective in treating adults

Merck cuts earnings guidance as acquisitions weigh on bottom line

IN BRIEF: Merck and Daiichi Sankyo's patritumab effective in phase 3

TOP NEWS: Merck swings to second-quarter profit; trims profit guidance

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités